Safety and tolerability of Pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) project

Circulation

Volumn 105, Issue 20, 2002, Pages 2341-2346

  Pfeffer, Marc A ^a   Keech, Anthony ^b   Sacks, Frank M ^a   Cobbe, Stuart M ^c   Tonkin, Andrew ^d   Byington, Robert P ^e   Davis, Barry R ^f   Friedman, Carola P ^g   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d NATIONAL HEART FOUNDATION OF AUSTRALIA   (Australia)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

Author keywords

Myositis; Pravastatin; Rhabdomyolysis; Safety; Statins

Indexed keywords

PLACEBO; PRAVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GALLBLADDER DISEASE; HUMAN; ISCHEMIC HEART DISEASE; LIVER DISEASE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MYALGIA; MYOSITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS;

AGED; ANTICHOLESTEREMIC AGENTS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; DEMOGRAPHY; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INCIDENCE; KIDNEY FAILURE; LIVER DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUSCULAR DISEASES; PRAVASTATIN; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RISK; RISK ASSESSMENT; TIME;

EID: 0037150209     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000017634.00171.24     Document Type: Article

References (22)

1. Primary prevention of coronary heart disease: Integrating risk assessment with intervention
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/Tex CAPS
7. Might treatment of hypercholesterolaemia increase noncardiac mortality?
8. The Lipid Research Clinics Coronary Primary Prevention Trial results II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
9. Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease
10. Carcinogenicity of lipid-lowering drugs
11. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: The role of metabolismmonograph for physicians
12. Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) Project: A combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS)
13. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin Pooling Project
14. Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project
15. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels: The Prospective Pravastatin Pooling project
16. Lessons from the glitazones: A story of drug development
17. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): Additional perspectives on tolerability of long-term treatment with lovastatin
18. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study
19. Learning from the cerivastatin experience